Castlight Health is seeing some major change ups in leadership this week. Yesterday the digital health company announced that its current CEO John Doyle is stepping down as director. The company has tapped Maeve O’Meara as the company’s next CEO. Siobhan Nolan Mangini will also join as the company’s next president, and maintains her position as chief financial officer.
"With the appointments of Maeve as CEO and Siobhan as President, the Castlight board is recognizing the exceptional leadership that both have provided as the company has scaled, as well as the impressive bench of talent Castlight has developed over the years," Judith Verhave, former global head of compensation and benefits for BNY Mellon and member of the Castlight Board of Directors, said in a statement. "Maeve and Siobhan have the vision and experience that Castlight needs to drive the company to the next chapter of growth."
Teladoc Health has named David Sides the next COO. Before joining the team Sides served as the CEO of Streamline Health. He also has experience on the payer side, working for Cerner for 17 years.
“As we continue to grow and diversify our global footprint, David’s proven ability to scale businesses across markets will be instrumental in our continued success,” Jason Gorevic, CEO, Teladoc Health, said in a statement. “We welcome David to the Teladoc Health team with the confidence that he is not only a strong operator and a thoughtful strategist, but also shares a deep commitment to our mission and values.”
This announcement comes six months after Teladoc’s VP, COO and CFO Mark Hirschhorn resigned amidst allegations that he engaged in an inappropriate sexual relationship with a subordinate and took part in insider trading. In December the telemedicine company was hit with a class action lawsuit filed on behalf of the company’s shareholders, which accused the company of misleading or false statements.
On Monday RenalytixAI, an AI enabled kidney disease diagnostics, announced that it tapped Thomas McLain as the next president and CCO. This isn’t McLain’s first go-round in the health sector. Before coming to RenalytixAI, he served as the president and CEO of Exosme Diagnostics. He was also the CEO of Vermillion and Claro Scientific.
"I am honored to welcome Tom to the RenalytixAI leadership team," James McCullough, CEO at RenalytixAI, said in a statement. "Tom's deep understanding of diagnostic product commercialization, healthcare markets and reimbursement will be a great asset to our company."
Verily’s Luba Greenwood has told MobiHealthNews that she will be leaving the Alphabet subsidiary to pursue lecturing at Harvard University as well continue her work on several boards.
Greenwood took up her role at Verily, where she served as the head of strategic business development and corporate ventures, in February of 2018. In a recent interview with MobiHealthNews, Greenwood discussed the importance of educating the upcoming workforce about the convergence of various disciplines making up digital health.
“This is exactly why I decided to teach the course at Harvard, which is actually a course within The Paulson School of Engineering — which is where computer sciences and engineering comes out of — together with the [Harvard] Graduate School of Design, [where] you want a true convergence,” Greenwood said. “So not just somebody that comes out of pure tech and tries to go into the clinical side, or somebody that comes out of medical school and takes a few computer science courses and is suddenly an expert. You really want to have ... the convergence of industry. And this is the piece that really needs to be built out ... making sure [on the academic side] that we are bringing in different expertise at the educational level. So here you have design, computer science, and now you put it together and then you think about how do you effect industry by combining these two areas.”